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Today, more than ever, basic science research provides significant opportunities to advance our
understanding about the genetic basis of human disease. Close interactions among laboratory,
computational, and clinical research communitieswill be crucial to ensure that genomic discoveries
advance medical science and, ultimately, improve human health.The potential for the burgeoning knowl-
edge of genome structure and function
to improve medical care has long been
anticipated (Collins, 1999), but until very
recently, the actual clinical application of
genomics has been limited (Green and
Guyer, 2011). Despite concerns about
the pace of medically relevant genomic
discoveries and the implementation of
genomic medicine (clinical care based
on or influenced by knowledge of a
patient’s specific genomic variants) (Var-
mus, 2010), growing numbers of en-
couraging examples are now in hand.
Early case reports of genomic-based
diagnoses leading to altered treatment
and an improved clinical course, facili-
tated by advancing genomic technologies
such as whole-exome and -genome se-
quencing, illustrate the potential of ge-
nomically informed medicine for im-
proving clinical care. Such reports also
demonstrate the critical role that basic
science approaches play in character-
izing implicated variants and pointing
toward more effective treatments. Here,
we describe several recent successes
in genomic medicine that illustrate the
critical interplay between basic and trans-
lational researchers that will be required
to make the routine use of genomic medi-
cine a reality.
The potential of whole-exome se-
quencing for identifying the genetic cause
of a mysterious and disabling disease
and, in some cases, for illuminating a
path toward effective treatment was
vividly demonstrated by the desperate
case of a young boy with severe, intrac-
table, and atypical inflammatory bowel
disease (Worthey et al., 2011). He failed14 Cell 147, September 30, 2011 ª2011 Elseto respond to conventional treatment
and progressively worsened. The only
treatment option remaining was hemato-
poietic stem cell transplantation. In the
absence of a clear diagnosis, clinicians
were concerned about subjecting the
boy to an invasive procedure with
unknown chances for survival. Whole-
exome sequencing provided the key di-
agnostic clue: a nonsynonymous change
in XIAP, a gene involved in apoptosis.
Functional studies quickly confirmed
that the mutation caused aberrant XIAP
function. These findings, and the known
morbidity risk of XIAP deficiency-related
hemophagocytic lymphohistiocytosis, tip-
ped the balance in favor of stem cell
transplantation. The patient survived the
procedure and is now well 1 year later (D.
Dimmock, personal communication).
There is little doubt among the clinical
and laboratory teams that this course
of treatment—a high-risk gamble justi-
fied only upon identification of the
presumed causal mutation—saved the
patient’s life.
Genomic analysis is a cornerstone
of the National Institutes of Health’s Undi-
agnosed Diseases Program (http://
rarediseases.info.nih.gov/Resources.aspx?
PageID=31), and it recently proved invalu-
able for studying three families with
severe, symptomatic arterial calcifica-
tions (St Hilaire et al., 2011). Several of
the affected individuals had disabling
intermittent claudication with extensive
occlusion of the iliofemoral arterial system
due to heavy calcification. One family
was consanguineous (a third-cousin
marriage), so genome-wide single-nucle-
otide polymorphism arrays were usedvier Inc.to identify genomic regions that were
homozygous in all affected siblings
but heterozygous in the unaffected
parents. The only such region included
three genes implicated in cellular path-
ways potentially involved in calcification.
One of these, NT5E, codes for the protein
CD73, which is involved in the same
pathway as a gene associated with gen-
eralized arterial calcification of infancy.
Targeted sequencing of the affected
siblings revealed a homozygous non-
sense mutation in NT5E, and quantitative
PCR analysis demonstrated decreased
NT5E expression in cultured fibroblasts
from two of the affected siblings. Studies
of two other affected families detected
missense and nonsense NT5E muta-
tions in homozygous or compound het-
erozygous states. A series of elegant
experiments revealed markedly reduced
CD73 levels and absent CD73 enzymatic
activity in fibroblasts from affected
patients, with the latter rescued by trans-
fection with a CD73-encoding lentiviral
vector. Fibroblasts carrying the NT5E
mutation also showed excessive staining
for tissue-nonspecific alkaline phos-
phatase (TNAP), a key enzyme for calcifi-
cation, as well as abundant calcium
phosphate crystal formation. These phe-
notypes were ameliorated by CD73 trans-
fection or treatment with either adenosine
or an inhibitor of alkaline phosphatase.
Elucidating the precise molecular defect
in this condition enables consideration
of treatments affecting other compo-
nents of this calcification pathway and
may shed light on potential treatments
for ectopic tissue calcification in other
disorders.
These two notable successes are en-
couraging, but it is sobering to recognize
that whole-genome analysis has failed to
reveal the cause of a rare genetic disease
in the majority of cases studied to date.
More robust approaches for genome
analysis are being developed to study
the thousands of genetic disorders for
which the molecular basis remains
unknown.
Pharmacogenomics is another area
where genomic discoveries can be lever-
aged to improve clinical care. Genotype-
targeted treatment with clopidogrel rep-
resents a prototypic pharmacogenomic
advance facilitated by basic science
investigation of the effect of specific
genetic variants. Clopidogrel is a widely
prescribed antiplatelet drug that binds to
the platelet P2Y12 receptor with wide
interindividual variability in response (Ro-
den and Shuldiner, 2010). Further study
of clopidogrel’s mechanism of action
showed that it is a pro-drug highly depen-
dent on cytochrome P450 2C19 for acti-
vation. Up to 30% of individuals carrying
CYP2C19 variants are unable to generate
the active form, and inhibition of platelet
aggregation was diminished in these indi-
viduals. Some, but not all, studies also
point to an associated higher risk for
thrombotic cardiovascular events among
these CYP2C19 variant carriers. An alter-
native but more costly anti-P2Y12 drug
does not require bioactivation, raising
the potential for genotype-targeted
selection of individuals needing the
higher-cost alternative. Another common
2C19 polymorphism can actually in-
crease clopidogrel metabolism, whereas
the effects of several rarer 2C19 variants
remain to be studied. Several pilot studies
are now underway examining the effec-
tiveness of pre-emptive genotyping in
patients. The effects of other 2C19
variants, the role of genotyping versus
phenotypic platelet inhibition assays,
and the therapeutic potential of other
antiplatelet drugs provide fertile ground
for basic science investigations that
can generate more effective treatments
to reduce the risk of thrombotic events.
Clinical outcome improvements like
these, in conjunction with appropriate
changes in physician and patient
behavior, will be essential for promoting
adoption of such genomic approaches in
routine clinical care. Findings from theseand related studies will also inform policy
development and regulatory oversight,
as illustrated by the Food and Drug





include the documented increased risk
for life-threatening adverse reactions to
carbamazepine in persons carrying the
HLA-B*1502 allele and the reduction of
that risk following genotyping and drug
avoidance by carriers of the risk allele
(Wilke and Dolan, 2011). HLA-mediated
risk for adverse drug reactions remains
poorly understood but is suspected to
involve HLA-allele-specific presentation
of key drug moieties to immune-acti-
vating cells—an area ripe for basic inves-
tigation.
Another potent pharmacogenomic
example is the BRAF kinase inhibitor
vemurafenib. Patients with metastatic
melanoma whose tumors carry the acti-
vating BRAF V600E somatic mutation
respond dramatically, with improved
rates of survival (Chapman et al., 2011).
The potential for vemurafenib and other
BRAF kinase inhibitors to improve health
spans of other cancer patients carrying
the BRAF V600E mutation is being in-
vestigated and may be an initial step in
the long-anticipated classification of
cancers based on molecular taxonomy
rather than organ of origin and histopa-
thology.
These examples demonstrate the
enormous potential of basic research to
contribute key insights about the pheno-
typic consequences of disease-associ-
ated variants that, in turn, lead to changes
in patient care. Although genetic variants
of large effect with clear functional impact
may be more readily identified in familial
or isolated cases of severe disease,
such as those described above, recent
studies have demonstrated the important
new areas of research catalyzed by
studying smaller-effect loci identified
in genome-wide association studies
(GWAS) (Ernst et al., 2011). For example,
80% or more of the genomic regions
implicated in the GWAS conducted
to date are intronic or intergenic (http://
www.genome.gov/gwastudies), with dis-
ease-associated variants being signifi-
cantly enriched in enhancer elementsCell 147, S(Ernst et al., 2011). Together, these find-
ings make detailed investigation of genet-
ically associated noncoding genomic
regions a high priority, yet our functional
understanding of noncoding regions is
in its relative infancy and will be compli-
cated by their greater genomic variation
compared to coding regions (1000
Genomes Project Consortium, 2010).
Variants in gene regulatory regions will
undoubtedly prove to be important in
disease causation, but their role in patho-
genesis will also be complex and difficult
to define compared to the coding variants
represented by the recent discoveries
described above and the overwhelming
majority of disease-causing mutations
reported to date.
For genomicmedicine to be successful,
basic science advances are also needed
to promote development of low-cost,
rapid, and clinically available technolo-
gies for detecting genomic variants.
Although the advent of genome-wide
genotyping arrays revolutionized identifi-
cation of disease-associated loci, this
and other genomic technologies (such
as genome sequencing) remain largely
unavailable outside major research labo-
ratories. The requisite data analysis and
quality control will likely keep these
technologies out of the typical clinical
laboratory for some time. This is unfortu-
nately also true for methods to detect
variants in targeted genes recognized to
have significant clinical implications.
Although becoming increasingly avail-
able, whole-exome and -genome se-
quencing presents significant challenges
with respect to data analysis, interpreta-
tion, and display. Robust yet easy-to-
utilize bioinformatic tools are urgently
needed for analyzing genome sequence
data, providing to clinicians only the infor-
mation about genomic variants that is
relevant to a patient’s care.
Our ability to define the role of genomic
variation in human disease is growing at
an ever-accelerating pace. As revealed
in the above examples, using these
advances to directly improve patient
care will require close interactions be-
tween the basic and clinical research
communities. The insights resulting from
genomic knowledge moving freely be-
tween the laboratory and the clinic hold
great promise for the implementation of
genomic medicine.eptember 30, 2011 ª2011 Elsevier Inc. 15
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